Novo Integrated Sciences, Inc. (NVOS): History, Ownership, Mission, How It Works & Makes Money

Do you defintely know how Novo Integrated Sciences, Inc. (NVOS), a microcap player with a trailing twelve-month revenue of $13.51 Million USD as of November 2025, is trying to disrupt the fragmented North American healthcare market? This isn't a typical clinic chain; their model is a unique, integrated blend of multidisciplinary primary care and proprietary wellness products, but its staggering $16.17 Million net loss in fiscal year 2024 raises serious questions about its capital-intensive growth strategy. If you are looking to understand the mechanics of this high-risk, high-potential OTC stock, you need to see the full picture: the history of strategic pivots, the integrated mission, and exactly how its decentralized model works to generate revenue.

Novo Integrated Sciences, Inc. (NVOS) History

You're looking for the origin story of Novo Integrated Sciences, Inc. (NVOS), and honestly, it's a textbook example of a public shell company executing a dramatic pivot. The company you see today-focused on multidisciplinary healthcare-didn't start there. It began life as an alternative energy and golf marketing venture before a critical acquisition in 2017 completely reshaped its mission.

The key takeaway is that the current healthcare entity is built on a foundation established over two decades ago, but its core business model is less than a decade old. This kind of history means you have to look past the initial incorporation to understand its true strategic trajectory.

Given Company's Founding Timeline

Year established

The legal entity was originally incorporated on November 27, 2000.

Original location

The company was initially incorporated in the State of Delaware, USA, before re-domiciling to Nevada in 2008. Its current corporate office is in Bellevue, Washington.

Founding team members

The company was founded by Michael H. Rouse. The current leadership is headed by Chairman and CEO, Robert Mattacchione.

Initial capital/funding

Specific initial seed funding for the original entity is not publicly detailed in recent filings. However, one of the earliest recorded capital injections was a conventional debt round of $433K on August 6, 2013.

Given Company's Evolution Milestones

Given Company's Transformative Moments

The company's history is defintely a series of radical shifts, but two moments stand out as truly transformative for the business you analyze today.

The first was the May 2017 acquisition of Novo Healthnet Limited. This wasn't just a new business line; it was a total corporate reversal, taking a shell company with a history in engine technology and golf, and immediately turning it into a provider of multidisciplinary primary care. This move created the entire revenue stream you see now, which is generated solely by services and products provided by the Canadian subsidiary.

The second key moment was the $15 million capital raise in December 2021. For a company that reported a net loss of $(4.462) million in the fiscal year ending August 31, 2021, securing $15 million in gross proceeds from a registered direct offering was a lifeline. Here's the quick math: that capital infusion was over three times the prior year's net loss, giving them runway to execute their integrated healthcare model, which you can read more about in their Mission Statement, Vision, & Core Values of Novo Integrated Sciences, Inc. (NVOS).

• The core business is now providing services like physiotherapy, chiropractic care, and eldercare, a complete departure from its 2000 founding concept.
• The focus on decentralized care, using technology to deliver services in clinics, long-term care, and retirement homes, is the direct result of the 2017 pivot.

What this estimate hides is the continued challenge: the company still reported a net loss of $(16.167) million for the fiscal year ending August 31, 2024, despite the capital raise and revenue growth. The strategy is clear-grow the integrated healthcare network-but the path to profitability is still a work in progress.

Novo Integrated Sciences, Inc. (NVOS) Ownership Structure

Novo Integrated Sciences, Inc. (NVOS) is a publicly traded company, and its ownership structure is heavily weighted toward individual retail investors, a common trait for micro-cap stocks with a low market capitalization.

This high retail ownership means stock movements are often driven by sentiment and trading volume rather than institutional analysis, so you defintely need to watch the daily volatility. The company's governance is steered by its Board of Directors and a small executive team, even as it operates with a NASDAQ symbol but trades at a low price point, sometimes being quoted on the OTC Markets Group.

Given Company's Current Status

As of November 2025, Novo Integrated Sciences is a publicly listed entity, trading under the ticker symbol NVOS. While it is listed on the NASDAQ Stock Exchange, its stock price of around $0.0050 per share as of November 21, 2025, places it in the micro-cap category, where it is also frequently quoted on the OTC Markets Group.

The company operates with a fiscal year ending on August 31, and its financial performance through the Trailing Twelve Months (TTM) ending in November 2025 shows a TTM Revenue of approximately $13.51 Million USD, but with a TTM Net Loss of about -$24.33 Million.

This financial reality-low revenue and significant net loss-is the core challenge facing the leadership team as they pursue their strategic goals outlined in the Mission Statement, Vision, & Core Values of Novo Integrated Sciences, Inc. (NVOS).

Given Company's Ownership Breakdown

The ownership structure of Novo Integrated Sciences is highly fragmented, with the vast majority of shares held by the public. This lack of significant institutional backing means there is less oversight from large, long-term fund managers, which can increase stock price volatility.

Here's the quick math on who controls the float, based on the most recent filings:

Given Company's Leadership

The company is steered by a small, focused executive team and a Board of Directors, with the leadership structure seeing a key change in early 2025.

• Robert Mattacchione: Chairman of the Board. He stepped down from the Chief Executive Officer role in February 2025 but remains the most senior executive on the Board.
• Christopher David: Chief Operating Officer (COO) and Director. He runs the day-to-day operations.
• Vivek Sethi: Principal Financial Officer (PFO) and Principal Accounting Officer. He oversees the financial reporting.
• Joseph Chalil: Chief Medical Officer and Chairman of the Medical Advisory Board. He provides clinical and strategic guidance for the healthcare services segment.

What this estimate hides is the current status of the CEO role, which was vacant after Mr. Mattacchione's resignation in February 2025, leaving the daily operational burden squarely on the COO and the Chairman.

Novo Integrated Sciences, Inc. (NVOS) Mission and Values

Novo Integrated Sciences, Inc. (NVOS) is built on a commitment to patient-first, integrated healthcare, which means blending traditional rehabilitative science with new medical technology to improve access and outcomes. This mission is the cultural anchor for a company that, despite reporting a net loss of over $16.17 million in its fiscal year 2024, is defintely focused on a transformative, long-term vision for decentralized care.

The company's core values go beyond its annual revenue of $13.29 million for the fiscal year ended August 31, 2024, centering instead on a multidisciplinary approach to wellness and community service.

Novo Integrated Sciences, Inc.'s Core Purpose

You need to know what a company stands for when you analyze its financials. For Novo Integrated Sciences, its purpose is to fundamentally change how primary care is delivered, moving away from siloed treatments toward a comprehensive, technology-enabled model.

Official mission statement

The mission is clear: to put the patient at the center of a holistic care model. This means integrating different specialties and technologies to cover the full spectrum of health, from assessment to prevention.

• Advance patient-centric care through rehabilitative science, advanced therapeutics, and medical technology.
• Provide excellence in multidisciplinary primary health care assessment, diagnosis, treatment, pain management, and prevention.
• Motivate clinicians to integrate medical technology and rehabilitative science for superior patient outcomes.

Vision statement

The vision is ambitious, mapping a future where healthcare is not just better, but more accessible and interconnected. Honestly, the goal is to build the next generation of healthcare companies by decentralizing services.

• Be a leader in building the next generation of healthcare companies.
• Achieve fundamental transformation in healthcare delivery by decentralizing care through medical technology and interconnectivity.
• Improve quality of life by expanding access to medical equipment and patient interface communications.
• Serve communities through high-quality service and unique care delivery settings, like in-clinic and long-term care facilities.

For a deeper dive into the numbers that support this vision, you should check out Breaking Down Novo Integrated Sciences, Inc. (NVOS) Financial Health: Key Insights for Investors.

Novo Integrated Sciences, Inc. slogan/tagline

While the company doesn't use a single, widely-marketed slogan, their core message is about integration and forward movement in patient care.

• Integrating Science. Advancing Patient Care.

Novo Integrated Sciences, Inc. (NVOS) How It Works

Novo Integrated Sciences, Inc. (NVOS) operates a decentralized healthcare model, integrating multidisciplinary primary care services with proprietary health and wellness products, primarily in Canada. The company creates value by using technology to connect patients with clinicians and products, moving non-catastrophic care beyond the traditional clinic setting.

Novo Integrated Sciences, Inc.'s Product/Service Portfolio

The company's revenue streams are split between its two core segments: direct healthcare services and product sales. For the trailing twelve months (TTM) ending around November 2025, Novo Integrated Sciences reported total revenue of approximately $13.51 Million USD. Here's the quick math: the Healthcare Services segment, which historically generates the majority of revenue, accounts for roughly 63% of that total, or about $8.51 Million USD, with Product Sales making up the remaining 37%, or approximately $5.00 Million USD.

Novo Integrated Sciences, Inc.'s Operational Framework

The operational model is built on three interconnected pillars to deliver care efficiently and cost-effectively, especially by minimizing the degradation of non-critical health conditions. The company operates a network of corporate-owned and affiliate clinics in Canada, but its value proposition is the seamless integration of technology.

• Service Networks: Manage and expand a network of multidisciplinary primary care clinicians providing services like occupational therapy, eldercare, and neurological rehabilitation.
• Interconnected Technology: Develop and deploy medical technology (MedTech) platforms, including telemedicine and remote patient monitoring, to expand service reach beyond physical clinics.
• Products: Use a science-first approach to develop and distribute personalized health and wellness products, focusing on preventative and maintenance care solutions.

This decentralized approach is defintely the core of their strategy.

Novo Integrated Sciences, Inc.'s Strategic Advantages

Novo Integrated Sciences' market success is enabled by a few clear strategic advantages that differentiate it in the competitive healthcare sector. You can learn more about the company's investor profile by Exploring Novo Integrated Sciences, Inc. (NVOS) Investor Profile: Who's Buying and Why?

• Integrated Care Model: Combining diverse clinical services with proprietary health products under one roof simplifies the patient journey and drives cross-selling opportunities.
• Decentralized Delivery: The commitment to technology-driven care, like telemedicine, expands the company's geographic reach without the capital expenditure of building new clinics, making care more accessible.
• Focus on Non-Catastrophic Care: By targeting preventative and rehabilitative care, the company positions itself in a segment that is essential for long-term health and cost-effective for the healthcare system.
• Product Ownership: Developing and distributing its own line of nutraceuticals and supplements (Product Sales segment) provides higher margin opportunities compared to relying solely on service fees.

The integration of medical technology with clinical expertise is the real differentiator.

Novo Integrated Sciences, Inc. (NVOS) How It Makes Money

Novo Integrated Sciences, Inc. primarily earns its revenue by providing a blend of multidisciplinary primary healthcare services and selling related health and wellness products directly to patients, mostly in Canada. The core of their financial engine is patient fees, which are typically covered through insurance programs or paid directly for various therapies and services.

Novo Integrated Sciences' Revenue Breakdown

To give you a precise look at where the money comes from, we have to use the latest complete fiscal year data, which is for the year ending August 31, 2024. The company's total annual revenue for that period was approximately $13.29 million. This breakdown shows you the reliance on the service side of the business.

Here's the quick math: Healthcare Services, which includes patient fees for physiotherapy, chiropractic care, and eldercare, brought in about $11.9 million of the total 2024 revenue. The overall revenue trend is positive, showing a modest growth of 5.75% year-over-year in 2024.

Business Economics

The company's economic fundamentals are tied to the fragmented Canadian healthcare facilities market, so competition is defintely a factor. Their strategy is to offer an integrated model, combining traditional medical services with complementary therapies like massage and acupuncture, to capture a broader patient base.

• Pricing Strategy: Revenue is largely driven by fee-for-service models, where the company bills patients or their insurance providers for specific treatments. Higher reimbursement rates are a key lever for future profitability, but they are hard to secure.
• Operational Core: Novo Integrated Sciences uses a network of owned and managed clinics, which helps them standardize clinical protocols and administrative functions for efficiency.
• Growth Levers: Future growth hinges on scaling up-either through acquiring smaller competitors or successfully executing on their financing and strategic partnership initiatives. You can read more about their vision here: Mission Statement, Vision, & Core Values of Novo Integrated Sciences, Inc. (NVOS).

The business model is built on three pillars: service networks, interconnected technology (like telemedicine), and health and wellness products, aiming for a decentralized care delivery. That integrated approach is the key differentiator.

Novo Integrated Sciences' Financial Performance

When you look at the financials, the picture is challenging despite the revenue growth. The company is not yet profitable and faces significant operational and financial headwinds.

• Total Revenue (FY 2024): Novo Integrated Sciences reported $13.29 million in total revenue for the fiscal year ending August 31, 2024.
• Net Loss (FY 2024): The company's net loss widened to approximately $(16.17) million in FY 2024. This is a serious cash drain.
• Net Margin (FY 2024): The net loss resulted in a net margin of -121.3%, meaning the company spends significantly more than it earns from its core operations.
• Operating Margin (FY 2024): The operating margin was -75.8%, which clearly shows that service delivery costs and general expenses are substantial relative to sales.
• Valuation Metric (TTM Nov 2025): The trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio as of November 2025 is -0.0111, which is typical for a company with a negative net income.

What this estimate hides is the high cost of revenues and operating expenses that consume a large portion of the gross profit, leading to the sustained net loss. The negative returns on equity and invested capital confirm that value creation is currently underwater. Your action should be to watch for any successful execution of their funding and acquisition strategy, as that is the only clear path to a turnaround.

Novo Integrated Sciences, Inc. (NVOS) Market Position & Future Outlook

Novo Integrated Sciences, Inc. operates in a hyper-fragmented North American physical therapy and integrated wellness market, where its current position is that of a nano-cap firm with a highly speculative, binary future tied almost entirely to the success of its pending non-dilutive financing initiatives.

The company's integrated care model is a solid concept, but its scale is minuscule compared to industry leaders, with a TTM revenue of approximately $13.5 million as of May 2024, which means its immediate trajectory hinges on securing transformational capital, not organic growth alone.

Competitive Landscape

You need to see the size difference to grasp the challenge. Novo Integrated Sciences, Inc. competes in the fragmented Canadian market against national chains and in the broader North American space against massive, diversified healthcare providers. Here's the quick math on market standing, using the Canadian physical therapy industry, estimated at around $11 billion, as a primary reference point for NVOS's core services.

Opportunities & Challenges

The company is at a make-or-break moment. The opportunity is truly transformational, but the risks are immediate and existential. This is a high-stakes, binary situation for shareholders.

Industry Position

Novo Integrated Sciences, Inc. is a nano-cap player in a large, growing industry. The U.S. physical therapy services market alone is projected to reach $49.48 billion in 2025, driven by an aging population and a shift toward non-opioid pain management.

The company's integrated model is its best asset, but it is defintely punching below its weight. Its current standing is defined by its financial structure, not its service offering.

• Scale Disparity: Revenue of $13.5 million is dwarfed by competitors like Select Medical Holdings, which projects 2025 revenue between $5.3 billion and $5.5 billion.
• Canadian Focus: The company is a small competitor in the Canadian physical therapy market, which is competitive and highly fragmented, with larger players like Lifemark Health Group holding a much greater share.
• Speculative Valuation: The entire valuation is a financing play right now. Investors are betting on the successful execution of the non-dilutive funding, which would instantly recapitalize the firm and allow it to pursue its Mission Statement, Vision, & Core Values of Novo Integrated Sciences, Inc. (NVOS).

The bottom line: The company has a sound strategic vision in a growing market, but its financial foundation is exceptionally weak, making it a high-risk, high-reward investment purely dependent on closing its announced funding deals.